Menu
The figure shows homologous recombination repair marker, RAD51 (red), in high-grade serous ovarian cancer tumor cell nuclei (blue).
New tool for tailoring drug treatment in ovarian cancer
Researchers at the Universities of Helsinki and Turku have developed a test to identify those ovarian cancer patients who benefit from traditional platinum-based chemotherapy as well as from a newer…
Exciting R2B funding news
iCAN had a strong showing in Business Finland’s last Research to Business funding round. Four out of eight projects funded at the University of Helsinki were from the iCAN community,…
New subprojects initiating in the iCAN Flagship Project
The iCAN Flagship Project has taken tremendous steps in 2022 with establishment of the pipeline for prospective sample collection and molecular profiling and establishment of the iCAN Discovery Platform where data analysis takes place in a safe environment. With the turn of the year another big change is taking place with initiation of the 2nd term of the Flagship Project with refined overall objectives and new host subprojects.